Core Insights - Abivax has presented new preclinical and clinical data for obefazimod, demonstrating its anti-fibrotic potential and favorable safety profile for treating inflammatory bowel disease at ECCO 2026 [2][3] Group 1: Clinical Data and Efficacy - The data presented includes evidence of obefazimod's anti-fibrotic effects in both preclinical human fibroblast models and in vivo animal models, indicating its potential to address unmet needs in Crohn's disease [4] - A pooled analysis from the Phase 3 ABTECT induction trials shows that obefazimod leads to symptomatic response as early as week 1 and symptomatic remission by week 2, with a nominally significant p-value of <0.05 [4][5] - Obefazimod demonstrated a ~50% reduction in a biomarker of active fibrosis (Pro-C3) and a ~30% reduction in a fibroblast activation marker (⍺SMA) in preclinical models, both with p-values <0.0001 [5] Group 2: Safety Profile - The safety data from the ABTECT-1 and ABTECT-2 trials indicate that the rates of serious treatment emergent adverse events (TEAEs) were comparable across treatment groups, with Obe-50mg at 3.1%, Obe-25mg at 2.2%, and placebo at 3.2% [8] - TEAEs leading to study discontinuation were also similar across groups, with Obe-50mg at 4.7%, Obe-25mg at 1.9%, and placebo at 4.1% [8] Group 3: Mechanism of Action - Biomarker data from the trials indicate that obefazimod enhances the expression of miR-124 and reduces key inflammatory cytokines IL-17A and IL-6 towards homeostatic levels, supporting its mechanism of action in restoring immune balance [4][8] - The mechanism allows for partial reduction of inflammatory cytokines without completely blocking these pathways, which may be beneficial for long-term disease management [8]

战略平台举措助力公司在 AI 驱动的实体 - 数字生态系统中实现规模化商业部署马来西亚吉隆坡, Feb. 21, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG，简称“VCI Global”或“公司”) 今日宣布成立 ROBODAX，这是一项战略平台举措，旨在将公司的机器人自动化路线图与现实世界资产 (RWA) 数字基础设施战略整合至单一执行架构之下。 ROBODAX 的成立标志着 VCI Global 向 AI 原生基础设施运营模式转型迈出了结构性一步。 该举措旨在将机器人自动化、AI 编排框架、通证化架构及企业结算能力整合为协同的平台战略，以助力未来商业部署。 ROBODAX 将作为架构执行层，连接实体自动化产出与数字资产基础设施。 随着时间推移，该框架有望支持商业化变现模式，将机器人产生的现实世界活动与通证化商业及基于交易所的结算机制相衔接。 尽管 ROBODAX 现阶段并非独立创收产品，但管理层认为，该举措通过将技术开发与规模化商业路径相结合，强化了公司的长期基础设施战略定位。 该平台架构旨在提升运营清晰度、资本配置规范性与执行效率， ...

马来西亚雪兰莪州, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Founder Group Limited (Nasdaq：FGL，以下简称“FGL”或“公司”) 今日宣布于 2026 年 2 月 17 日收到 Nasdaq Stock Market LLC (以下简称“Nasdaq”) 上市资格审查部的通知函。函件指出，因公司已不再满足 Nasdaq 资本市场 Nasdaq 上市规则 5550(a)(4) 规定的 50 万股最低公众持股量要求，故不再符合持续上市的上市规则。 该通知不会对公司 A 类普通股的上市及交易造成即时影响。 公司须在 2026 年 4 月 3 日之前向 Nasdaq 工作人员提交一份具体计划，说明如何实现并持续满足 Nasdaq 资本市场所有上市要求，包括完成该计划的时间表。 公司拟在规定期限内提交该计划。 关于 FGL Founder Group Limited 是一家专注于马来西亚太阳能光伏 (PV) 设施的全流程工程、采购、建设和调试 (EPCC) 解决方案提供商。 公司的主要业务集中在两个关键领域：大型太阳能项目以及商业和工业 (C&I) 太阳能项目。 ...

Market Overview - The video management software market was valued at USD 14.02 billion in 2025 and is projected to reach USD 42.72 billion by 2033, growing at a CAGR of 14.94% from 2026 to 2033 [1] - The U.S. video management software market is expected to grow from USD 5.33 billion in 2025 to USD 16.23 billion by 2033, with a CAGR of 14.20% [3] Growth Drivers - Key factors driving market growth include the demand for intelligent video surveillance systems across sectors such as BFSI, transportation, government, and retail [1] - Increasing deployment of IP-based surveillance systems, investments in smart city infrastructure, and the demand for cloud-based solutions are significant contributors to market expansion [3] Segmentation Analysis By Technology - Analog-based video systems held 68% of the market share in 2025, primarily due to their presence in developing regions [4] - IP-based video management systems are rapidly growing, driven by advancements in technology such as higher resolution and AI integration [4] By Deployment - The on-premises segment accounted for 71% of revenue share in 2025, favored for its control and data security [5] - The cloud segment is experiencing rapid growth due to its scalability and integration with AI tools [5] By Application - The video analytics segment dominated the market in 2025, while remote monitoring is the fastest-growing segment due to the rise of cloud-based systems [7] By Vertical - Retail and e-commerce led the market in 2025, while healthcare is the fastest-growing vertical due to increased surveillance needs [8] Regional Insights - North America dominated the market in 2025 with a 36% revenue share, attributed to early adoption of advanced surveillance technologies [9] - Asia-Pacific is expected to grow the fastest during the forecast period, driven by urbanization and smart city initiatives [10] Market Trends - The increasing demand for real-time surveillance in urban and critical infrastructure settings is a primary factor for market expansion [11] - Investments in advanced video management systems by large corporations and government organizations are enhancing operational monitoring and public safety [11] Key Players - Major companies in the video management software market include Milestone Systems, Genetec Inc., Avigilon, Bosch Security Systems, and Honeywell International Inc. [14] Recent Developments - Milestone Systems launched XProtect 2024R2 in March 2025, enhancing cloud-connected management and AI integration [15] - Genetec Inc. unveiled Security Center SaaS in January 2025, emphasizing its leadership in cloud-first deployments [16]

Core Insights - The Jay Walker Podcast has entered a distribution agreement with Tubi, the largest ad-supported streaming service, to transition to a weekly televised format starting Summer 2026, while also making its entire library available for global streaming [2][3][4] - The podcast has achieved over 100 million downloads, establishing itself as a leading platform for culturally relevant storytelling and discussions with notable figures [3] - The partnership aims to enhance audience engagement by providing a cinematic experience while maintaining availability across all major podcast platforms [4][5] Company Overview - Jay Walker is a media executive and host of The Jay Walker Podcast, focusing on building brands and networks that blend culture, faith, and leadership [7] - WoahRae, the production company founded by Jay Walker, specializes in creating original content that resonates culturally and emphasizes ownership and leverage in media [8]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Class A common stock of NuScale Power Corporation, alleging misleading statements and undisclosed risks related to the company's commercialization strategy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of NuScale Class A common stock between May 13, 2025, and November 6, 2025 [1]. - The lawsuit claims that NuScale made false and misleading statements regarding ENTRA1 Energy LLC's experience and capabilities in nuclear power generation, which were critical to NuScale's commercialization strategy [5]. - The lawsuit alleges that ENTRA1 had never built or operated significant projects in the nuclear power field, exposing NuScale to undisclosed risks of failure and regulatory challenges [5]. Group 2: Participation Information - Investors who purchased NuScale Class A common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by April 20, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm Background - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - The Corcept class action lawsuit alleges that Corcept Therapeutics and its executives misrepresented the status of their New Drug Application (NDA) for relacorilant, leading to significant financial losses for investors when the FDA issued a Complete Response Letter (CRL) indicating concerns about the clinical evidence supporting the NDA [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Corcept common stock from October 31, 2024, to December 30, 2025 [1]. - The lawsuit is titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated and is filed in the Northern District of California [1]. - The allegations include that Corcept misled investors about the FDA's review process and the adequacy of clinical evidence for relacorilant [3][4]. Group 2: FDA Concerns - The FDA had raised concerns about the clinical evidence supporting the NDA for relacorilant, indicating a material risk of non-approval [3]. - On December 31, 2025, Corcept disclosed that the FDA issued a CRL, stating it could not make a favorable benefit-risk assessment without additional evidence [4]. - A redacted copy of the CRL published on January 30, 2026, detailed the FDA's concerns regarding the sufficiency of the clinical studies submitted [5]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - Rosen Law Firm is reminding sellers of Masonite International Corporation common stock of a class action lawsuit with a lead plaintiff deadline of April 7, 2026, for those who sold shares between June 5, 2023, and February 8, 2024 [1] Group 1: Class Action Details - A class action lawsuit has been filed against Masonite for material omissions and misrepresentations regarding Owens Corning's offers to purchase Masonite's stock at significant premiums, which were not disclosed to investors [4] - Investors who sold Masonite common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3] - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [3] Group 3: Next Steps for Investors - Interested investors can join the Masonite class action by visiting the provided link or contacting the firm directly for more information [2][5] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [6]

Core Viewpoint - Rakovina Therapeutics Inc. has announced an upsized financing plan totaling approximately $2 million, which includes a convertible debenture and a common share private placement to support near-term operations [1][4]. Financing Details - The financing consists of a non-brokered private placement of an unsecured convertible debenture for $1.0 million, along with two million common share purchase warrants, with each warrant exercisable at $0.20 per share until January 28, 2029 [2][9]. - Concurrently, the company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share, aiming for additional gross proceeds of up to approximately $1.0 million [3]. Use of Proceeds - The aggregate gross proceeds from the private placements will be utilized for near-term working capital to support ongoing corporate activities and strategic initiatives while evaluating longer-term financing alternatives [4]. Regulatory Approvals - The closing of the private placements is contingent upon obtaining all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically targeting the DNA-damage response [6][7].

TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- FT Portfolios Canada Co. (“First Trust Canada”), announced today that the cap, buffer and dates for the next Target Outcome Period for the First Trust Vest U.S. Equity Buffer ETF – February (FEBB.F) (the “fund” or “February Buffer ETF”) are as follows: TICKER CAPBUFFEROUTCOME PERIODFEBB.F 15.05% (Gross)10%23/02/2026 – 19/02/2027      The previous Target Outcome Period for FEBB.F concluded on February 20, 2026 and the upside cap for the new Target Outcome Period has ...